logo

Endocrine Society of Australia Position Statement on Testosterone (Part 2)

The final section of the Endocrine Society of Australia (ESA) Position Statement on Male Hypogonadism (Part 2: treatment and therapeutic considerations) was published in the September issue of the Medical Journal of Australia, complementing Part 1: assessment and indications for testosterone therapy.

testosterone-vial-343x480Developed by leading Australian endocrinologists, including Andrology Australia Director Professor Rob McLachlan, the position statement supports the use of testosterone replacement therapy in men of any age with confirmed androgen deficiency.

Part 2 of the statement highlights that the evidence regarding testosterone treatment and cardiovascular outcomes is weak and inconclusive. Until better evidence is available the statement advises caution with using testosterone in older men with cardiovascular disease, especially those without a confirmed androgen deficiency diagnosis. Further research is needed to see if testosterone therapy in these cases is safe and effective.

Men should speak to their treating doctor before making any decisions about treatment with testosterone. The ESA statement will help doctors in identifying, diagnosing and treating patients with androgen deficiency.

To help guide medical professionals, Andrology Australia, in cooperation with the ESA developed an advisory note outlining the Pharmaceutical Benefits Schedule (PBS) criteria for prescribing testosterone (for medical professionals).

In summary:

The final section of the Endocrine Society of Australia (ESA) Position Statement on Male Hypogonadism (Part 2: treatment and therapeutic considerations) was published in the September issue of the Medical Journal of Australia, complementing Part 1: assessment and indications for … Continue reading

Men's health in Primary Health Care

The text and summary of this article may be used by primary health care organisations (such as Medicare Locals and Community Health Services) and peak health professional organisations (such as APNA and AAPM) to inform their staff and/or health professional members.

Organisations such as those listed above may republish this article in their own publications (including newsletters, web sites, fax and email bulletins) for their own staff and to health professional members.

Note that copyright applies to this material and the following credit must be included when republishing:
Copyright © Andrology Australia (www.andrologyaustralia.org)

Unless specified otherwise, non-text elements (e.g. images, video) may not be republished.

Read more articles on the 'Primary health care' blog.

This entry was posted in Clinical management, Men's health, Primary health care, Testosterone. Bookmark the permalink.
Website by Essendon Creative